The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.
However, the market for all inhalation-related diseases, specifically idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), plus COPD and asthma, amounted to $28.1 billion in 2015 and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback